Laidlaw Wealth Management LLC Sells 982 Shares of Eli Lilly and Company $LLY

Key Points

• Laidlaw Wealth Management LLC reduced its stake in Eli Lilly and Company by 52.3%, selling 982 shares and retaining 896 shares, making it the fund's 14th largest holding.
• Eli Lilly recently reported a strong financial performance for the quarter with earnings of $6.31 per share, surpassing analysts' expectations, and a revenue of $15.56 billion, which is up 37.6% year-over-year.
• The company announced a quarterly dividend of $1.50 per share, with a dividend yield of 0.8%, reflecting a dividend payout ratio of 39.22%.

Laidlaw Wealth Management LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 52.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 896 shares of the company's stock after selling 982 shares during the quarter. Eli Lilly and Company accounts for about 2.2% of Laidlaw Wealth Management LLC's investment portfolio, making the stock its 14th largest holding. Laidlaw Wealth Management LLC's holdings in Eli Lilly and Company were worth $740,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of LLY. Brighton Jones LLC boosted its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after buying an additional 40 shares in the last quarter. Orion Capital Management LLC raised its position in Eli Lilly and Company by 2.5% in the 4th quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock valued at $1,243,000 after buying an additional 40 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its stake in Eli Lilly and Company by 4.1% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock valued at $49,993,000 after acquiring an additional 2,568 shares in the last quarter. Finally, Breed s Hill Capital LLC grew its stake in shares of Eli Lilly and Company by 212.0% during the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock worth $1,101,000 after acquiring an additional 969 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Activity

In related news, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $11.35 during midday trading on Tuesday, reaching $749.99. 2,983,536 shares of the company's stock were exchanged, compared to its average volume of 4,436,129. The stock's 50-day simple moving average is $742.49 and its 200 day simple moving average is $779.42. The firm has a market cap of $709.84 billion, a price-to-earnings ratio of 49.02, a P/E/G ratio of 1.03 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the firm posted $3.92 earnings per share. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is 39.22%.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. Guggenheim cut their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. Leerink Partners reissued a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their price target for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.